Group 1 - The company reported total revenue of $399 million for the year ending December 31, 2024, representing a year-on-year increase of 49.59% [1] - Revenue growth was primarily driven by the strong commercialization of Weiwei Jia since its launch in September 2023 and its inclusion in the national medical insurance catalog in January 2024 [1] - The company continues to maintain its leading position in the ovarian cancer PARP inhibitor market and has seen steady sales growth from its products included in the national medical insurance catalog [1] Group 2 - The company achieved positive results in the global Phase I study of ZL-1310, a targeted DLL3 ADC for the treatment of extensive small cell lung cancer [2] - Encouraging preclinical data was obtained for ZL-1503, a dual-specific antibody targeting IL-13/IL-31R for the treatment of atopic dermatitis [2] - The company expanded its product pipeline through strategic collaborations, including a partnership with Yilian Bio to develop ZL-6201, a novel targeted LRRC15 ADC for specific solid tumors [2]
再鼎医药(09688)发布年度业绩 总收入3.99亿美元 同比增加49.59%